Stem cell genes are helping inform this startup’s approach to cancer diagnostics
The same genes in stem cells and cancer cells are being expressed. OncoCyte is using this knowledge to develop a genetic diagnostic test.
Regenerative medicine startup Cell Targeting sold to BioTime
Cleveland stem cell technology developer Cell Targeting has sold its assets to BioTime, which specializes in stem cells for use in regenerative medicine and blood plasma volume expanders for use in surgery. The deal includes $250,000 in cash and about 262,000 shares of BioTime's common stock. Joseph Wagner, Cell Targeting's president, will become the chief executive at OncoCyte, a BioTime subsidiary.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Weekend Rounds: Cleveland company aims stem cell therapies at targets
In the last week at MedCity News: Cell Targeting in Cleveland points stem cell therapies to specific areas of the body, Cleveland insurance broker and risk manager Oswald Cos. assembles panel that says health care reforms are too close to call, and Ohio State University and Battelle try to energize joint research and economic development efforts.
Cell Targeting hopes to bring purpose to stem cell therapy
Cell Targeting is developing technology that can point stem cell therapies to specific areas of the body. Among the many challenges in cell therapy is direction: not enough of the stem cells are getting to the tissues that needs treatment. But the company also wants to sell companies (and investors) on the idea that Cell Targeting's approach can create new products.
Cleveland stem cell projects receive $10 million commercialization boost
The money will push two stem-cell technologies deeper into clinical trials and create Ohio's first Pluripotent Stem Cell Facility.
Cell Targeting Inc. adds CTO, hopeful for new stem cell opportunities
CLEVELAND, Ohio — Stem-cell companies may be able to blunt the economic doldrums of 2009 with new opportunities courtesy of a new administration, according to the interim chief executive of Cleveland’s Cell Targeting Inc. Cell Targeting on Thursday said it appointed Joseph Wagner as its chief technology officer. Wagner for the last seven years worked […]
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.